Noxopharm Earns CSL Spotlight at World’s Biggest Influenza Conference
CSL to present Noxopharm’s Sofra™ data at world’s largest influenza conference
Data from a project involving Noxopharm Limited’s Sofra™ technology platform is set to be presented by CSL, a global biopharma company, at the Options for the Control of Influenza XIII Conference in late August 2026 in Washington DC. The presentation centres on how Noxopharm’s novel oligonucleotides from Sofra™ could improve the delivery of self-amplifying mRNA vaccines.
Critically, this is a CSL-led presentation, not one organised by Noxopharm itself. That distinction matters: it reflects external interest from a recognised global industry player, lending meaningful credibility to the Sofra™ platform at a scientific level.
When big ASX news breaks, our subscribers know first
What is Sofra™ and why does it matter?
A platform built on a breakthrough in immune science
Sofra™ is built on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These sequences act on specific immune sensors to regulate inflammation at its source, either reducing or stimulating it to help control disease.
The platform is designed to precisely regulate innate immune signalling (the body’s first-line immune response), with potential applications spanning:
- Rheumatoid arthritis
- Lupus
- Diabetes
- Oncology
- Off-target effects of RNA therapeutics
This breadth of application positions Sofra™ as a multi-indication platform rather than a single-disease asset.
A market opportunity worth hundreds of billions
The commercial backdrop against which Sofra™ is being validated is substantial. According to figures cited in the announcement:
| Market | 2023/2024 Value | Projected Value | Projection Year |
|---|---|---|---|
| Global autoimmune disease therapeutics | US$163.2 billion (2024) | US$219.6 billion | 2035 |
| Worldwide immuno-oncology | US$43 billion (2023) | US$284 billion | 2033 |
Sofra™’s ability to address both of these markets underlines why interest from a global biopharma such as CSL carries weight beyond a single conference appearance.
Industry interest signals growing momentum for Noxopharm
The Options for the Control of Influenza XIII Conference is the largest global scientific meeting focused on influenza prevention, control, and treatment. It brings together world-leading experts in virology, clinical care, public health, and vaccine research to share the latest evidence and advance the global response to influenza. Having Sofra™ data featured at this forum, presented by CSL, reflects the platform’s growing credibility among serious scientific stakeholders.
No commercial agreement between CSL and Noxopharm has been announced. However, the selection of Sofra™ data for such a prominent forum suggests the platform is attracting attention that extends well beyond Noxopharm’s own research community.
CEO Commentary
“The Sofra platform could be used in many areas where inflammation plays a role, and we have made significant progress bringing it to a point where it is attracting attention not only because of its versatility, but also because of the breakthrough understanding of the immune system on which it is based.”
Dr Olivier Laczka, Chief Executive Officer, Noxopharm
Noxopharm operates across two proprietary technology platforms: Sofra™, which targets inflammation, autoimmunity, mRNA drug enhancement, and oncology, and Chroma™, focused on oncology. Together, they underpin the company’s positioning as a clinical-stage biotech with a growing proprietary drug pipeline.
The next major ASX story will hit our subscribers first
What to watch next
Investors following the Sofra™ story should monitor three near-term developments:
- The CSL presentation at the Options for the Control of Influenza XIII Conference, scheduled for late August 2026 in Washington DC
- Any further data or publications that may emerge from the CSL and Sofra™ collaboration
- Broader Sofra™ platform progress across its other indication areas, including autoimmunity and oncology
No commercial outcomes have been confirmed at this stage, and investors should note that forward-looking statements carry inherent uncertainty.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare and biotech news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button to start receiving real-time coverage today.